Guidelines for pediatric management of severe chronic neutropenia
dc.contributor.author | Dale, David C. | en_US |
dc.contributor.author | Boxer, Laurence A. | en_US |
dc.date.accessioned | 2012-03-16T16:02:01Z | |
dc.date.available | 2013-04-01T14:17:26Z | en_US |
dc.date.issued | 2012-02 | en_US |
dc.identifier.citation | Dale, David C.; Boxer, Laurence A. (2012). "Guidelines for pediatric management of severe chronic neutropenia ." American Journal of Hematology 87(2): 133-133. <http://hdl.handle.net/2027.42/90415> | en_US |
dc.identifier.issn | 0361-8609 | en_US |
dc.identifier.issn | 1096-8652 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90415 | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Guidelines for pediatric management of severe chronic neutropenia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Deptartment of Medicine, University of Washington, Seattle, Washington | en_US |
dc.contributor.affiliationother | University of Washington, Box 356422, 1959 NE Pacific St., Rm AA522, Seattle, WA 98195 | en_US |
dc.identifier.pmid | 22237723 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90415/1/23107_ftp.pdf | |
dc.identifier.doi | 10.1002/ajh.23107 | en_US |
dc.identifier.source | American Journal of Hematology | en_US |
dc.identifier.citedreference | Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2‐, HAX1‐, and GCSF‐receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144: 459 – 467. | en_US |
dc.identifier.citedreference | Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony‐stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81: 2496 – 2502. | en_US |
dc.identifier.citedreference | Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long‐term risk of leukaemia in patients with severe congenital neutropenia maintained on G‐CSF therapy. Br J Haematol 2010; 150: 196 – 199. | en_US |
dc.identifier.citedreference | Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long‐term G‐CSF therapy. Blood 2006; 107: 4628 – 4635. | en_US |
dc.identifier.citedreference | Dale DC, Bolyard AA, Schwinzer BG, et al. The Severe Chronic Neutropenia International Registry: 10‐year follow‐up report. Support Cancer Ther 2006; 3: 220 – 231. | en_US |
dc.identifier.citedreference | Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82 – 93. | en_US |
dc.identifier.citedreference | Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenias: Consensus guidelines on therapy and follow‐up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato‐Oncologia Pediatrica). Am J Hematol 2011 [Epub ahead of print]. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.